ArticleBMC pulmonary medicine2025
A novel tool to predict the probability of pulmonary metastasis in patients with primary osseous sacral/pelvic tumors: a large real-world multicenter study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with primary osseous sacral/pelvic tumors, once pulmonary metastasis has occurred, their prognosis is worrying. It is therefore essential to construct a novel tool to achieve accurate prediction of the probability of pulmonary metastasis from primary osseous sacral/pelvic tumors.
methodsThis study retrospectively analyzed data from 407 patients with primary osseous sacral/pelvic tumors from the Surveillance, Epidemiology, and End Results database. Univariate and multivariate logistic regression analyses were used to identify risk factors. Construction of predictive models based on logistic regression algorithm in R software. The calibration, discrimination, and clinical utility of the models are validated in a validation cohort. The Kaplan-Meier survival curve and log-rank test were used to examine the pulmonary metastasis risk classification system for evaluation.
resultsThe total cohort was randomly divided into a training cohort (287 patients) and a validation cohort (120 patients). Five independent risk factors were identified to develop a nomogram model to predict the probability of pulmonary metastasis in patients. The area under the receiver operating characteristic curve (0.860 for the training cohort and 0.895 for the validation cohort) showed that the model showed satisfactory discrimination in both validation cohorts. The calibration curve showed a high predictive accuracy of the model and the Hosmer-Lemeshow test indicated a good model fit (p > 0.05). The decision curve analysis showed that the nomogram is clinically useful and can provide a net benefit to patients within certain limits.
conclusionWe have successfully developed a nomogram and risk classification system to accurately predict the probability of pulmonary metastasis from primary osseous sacral/pelvic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.